Page 94 - Sohini Das

Sun Pharma's Q2 net profit rises 70% on one-time tax credit

Revenues remain flat, sequential improvement in India and US revenues

Listing can happen in 18-24 months, says Manipal Education's Ranjan Pai

Our focus right now is to complete the transaction and the integration, said Pai

Bengaluru-based Manipal Hospitals to acquire Columbia Asia for Rs 2,100 cr

The deal may mark the exit of US based hospital chain from India

DCGI rejects DRL's proposal, denies full marketing rights for Remdesivir

Emergency use authorisation to continue; recently, WHO had raised doubts about efficacy of drug in treatment of Covid-19 patients

Covid-19 vaccine: India begins augmenting its cold chain capacity

While the country already has a huge cold chain set-up, it may not be enough for vaccine delivery

Decoded: Why the fear of a second coronavirus wave in India is real

Europe is now suffering from a second wave of the Sars-CoV-2 virus attack

Govt revises PLI scheme for bulk drugs to boost local manufacturing

Industry says revised PLI scheme will attract more MSMEs to invest as minimum investment clause done away with

Syringe, vial makers ramp up capacity amid Covid-19 vaccine hopes

The first of a two-part series looks at the ways in which the supply chain for the delivery of the Covid-19 vaccine is being bolstered

Covid-19: Dr Reddy's engages Indian partners to develop Sputnik V

Sputnik V is also undergoing Phase 3 clinical trials in Russia and other parts of the globe on 40,000 volunteers

Aurobindo Pharma to sell US-based Natrol for about Rs 4,048 crore

Aurobindo's stock reacted positively to the news, going up in morning trade but later settled flat at Rs 784.65 on the BSE

Investigational therapy: Ozone next in the mix to help fight Covid-19

It has the potential of an immunity-boosting prophylactic and can help ease post-Covid-19 complications

Bharat Biotech starts Covaxin's at-risk manufacturing; expanding capacity

The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results.

Covid-19: Bharat Biotech cuts Covaxin phase-2 clinical trial size by half

For phase-2 studies, the firm is also testing the vaccine on children above 12 years of age. In phase-1, they only tested adults.

Indian samples of global Covid-19 vaccines need to be larger: Experts

Indian players like Bharat Biotech and Zydus Cadila ready for large-scale phase-3 trials

Smaller pharma firms post faster domestic sales growth in September

Barring Cipla and Glenmark, whose sales have grown in double digits due to demand for their Covid-19 drugs like favipiravir, tocilizumab, most big players have posted tepid growth

Govt begins micro-planning for administering Covid-19 vaccine to the masses

Centre has asked states to update databases, train manpower, indicate resource requirements

We can make over 1.5 bn doses in 2021: Biological E MD & CEO Mahima Datla

Though our target is a billion doses, we may have an upside as we are evaluating various doses in the phase-1 and -2 studies, said Datla

Immunity hurdle for a shot at Covid vaccine; govt working on priority list

Rapid antibody tests at dedicated Covid-19 vaccination centres to act as screening tool

Piramal Pharma readies war chest for potential acquisition targets

A decade after Piramal sold its domestic formulations business to Abbott Laboratories for $3.72 billion, the group is now looking at re-entering the space in India

Cardiac, vitamin drugs see pharma sales rebound with 4.5% growth in Sept

Industry says fresh prescriptions are picking up